Five Prime's lesson in never giving up
The group’s restructuring, C-suite clearout and refocusing on bemarituzumab is rewarded with a $1.9bn buyout by Amgen.
The bull case for Vir starts to unravel
Hopes for the highly valued biotech’s Covid-19 antibody dim before a more important look at the project’s potential.
March medtech merger madness
High asset prices and a need to release the pandemic’s brake on growth force medtechs to splash the cash.
